Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors

Atherosclerosis

Volumn 145, Issue 2, 1999, Pages 325-331

  Alfon, José ^a   Guasch, Joan F ^a   Berrozpe, María ^a   Badimon, Lina ^a  

^a CSIC   (Spain)

Author keywords

Fibrinogen; Macrophages; Monocyte chemoattractant protein 1; Nitric oxide synthase II; Smooth muscle cells

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; MACROPHAGE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE FIBER;

ANIMALS; ARTERIOSCLEROSIS; CHEMOKINE CCL2; CHOLESTEROL; CHOLESTEROL, DIETARY; DISEASE MODELS, ANIMAL; DNA; DOWN-REGULATION; FIBRINOGEN; GENE EXPRESSION; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; POLYMERASE CHAIN REACTION; PYRROLES; RABBITS; SIMVASTATIN; TUNICA INTIMA;

EID: 0032773480     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00084-2     Document Type: Article

References (35)

1. Illingworth DR, Erkeleus DW, Keller U, Thompson G, Tikkanen MJ. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin and simvastatin. Lancet 1994;343:1554-5.
2. Scandinavian Simvastatin Survival Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Krause BR, Bousley R, Kieft K, Stanfield R, Newton RS. CI-981 is superior to lovastatin for lowering triglycerides in experimental animals (abstract). FASEB J 1993;7:A567.
4. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J Am Med Assoc 1996;275:128-33.
5. Nawrocki JW, Weiss SR, Davidson MD, Sprecher DL, Schwartz SL, Lupien P-J, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995;15:678-82.
6. Vaugham CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet 1996;348:1079-82.
7. Alfon J, Pueyo Palazon C, Badimon L. Inhibitors of hydroxymethyl glutaryl CoA reductase as modulators of intimal thickening in diet-induced atherosclerorosis (abstract). Atherosclerosis 1997;134:119.
8. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, et al. Minimally modified LDL induces monocyte chemotactic protein 1 in human endothelial and smooth muscle cells. Proc Natl Acad Sci USA 1990;87:5134-8.
9. Shyy Y-J, Hsieh H-J, Usami S, Chien S. Fluid shear stress induces a biphasic response of human monocyte chemotactic protein 1 gene expression in vascular endothelium. Proc Natl Acad Sci USA 1994;91:4678-82.
10. Yu X, Dluz S, Graves DT, Zhang L, Antoniades HN, Hollander W, et al. Elevated expression of monocyte chemoattractant protein 1 by vascular smooth muscle cells in hypercholesterolemic primates. Proc Natl Acad Sci USA 1992;89:6953-7.
11. Hibbs Jr JB, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1988;157:87-94.
12. Radomski MW, Palmer RMJ, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 1990;87:10043-7.
13. McCall TB, Palmer RMJ, Moncada S. Induction of nitric oxide synthase in rat peritoneal neutrophils and its inhibition by dexamethasone. Eur J Immunol 1991;21:2523-7.
14. Knowles RG, Merrett M, Salter M, Moncada S. Differential induction of brain, lung and liver nitric oxide synthase by endotoxin in the rat. Biochem J 1990;270:833-6.
15. Hibbs Jr JB, Taintor RR, Vavrin Z, Granger DL, Drapier J-C, Amber IJ, et al. Synthesis of nitric oxide from a terminal guanidino nitrogen atom of L-arginine: a molecular mechanism regulating cellular proliferation that targets intracellular iron. In: Moncada S, Higgs EA, editors. Nitric Oxide from L-arginine: a bioregulatory system. Amsterdam: Elsevier, 1990:189-223.
16. Stuehr DJ, Cho HJ, Kwon NS, Weise MF, Nathan CF. Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci USA 1991;88:7773-8.
17. White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D, et al. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 1994;91:1044-8.
18. Böger RH, Bode-Böger SM, Frölich JC. The L-arginine-nitric oxide pathway: role in the atherosclerosis and therapeutic implications. Atherosclerosis 1996;127:1-11.
19. Xie Q-W, Kashiwabara Y, Nathan D. Role of transcription factor NF-κB in induction of nitric oxide synthase. J Biol Chem 1994;269:4705-8.
20. Barnes PJ. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
21. Collins T. Endothelial nuclear factor NF-κB and the initiation of atherosclerotic lesions. Lab Invest 1993;68:499-508.
22. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995;76:980-6.
23. Van Heek M, Zilversmit DB. Mechanisms of hypertriglyceridemia in the coconut oil/cholesterol-fed rabbit. Increased secretion and decreased catabolism of very low density lipoprotein. Arterioscler Thromb 1991;11:918-27.
24. Van Heek M, Zilversmit DB. Evidence for an inverse relation between plasma triglycerides and aortic cholesterol in the coconut oil/cholesterol-fed rabbit. Atherosclerosis 1988;71:185-92.
25. Bocan TMA, Mazur MJ, Mueller SB, Brown EQ, Sliskovic DR, O'Brien PM, et al. Antiatherosclerotic activity of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase in cholesterol-fed rabbits: a biochemical and morphological evaluation. Atherosclerosis 1994;111:127-42.
26. Sambrook J, Fritsch EF, Maniatis T. Extraction, purification and cellular analysis of messenger RNA from eukaryotic cells. In: Molecular cloning: a laboratory manual, 2nd. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1989:7.19-22.
27. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983;50:127-34.
28. Fernández-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994;23:1562-9.
29. Martinez-Gonzalez J, Badimon L. Human and porcine smooth muscle cells share similar proliferation dependence on the mevalonate pathway. Implications for in vivo interventions in the porcine model. Eur J Clin Invest 1996;26:1023-32.
30. Hidaka Y, Eda T, Yonemoto M, Kamei T. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 1992;95:87-94.
31. Negre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE, Cohen LH. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types. Biochim Biophys Acta 1997;1345:259-68.
32. Ylä-Herttuala S, Lipton BA, Rosenfeld ME, Särkioja T, Yoshimura T, Leonard EJ, et al. Expression of monocyte chemoattractant protein 1 in macrophage rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991;88:5252-6.
33. Bustos C, Hernández-Presa MA, Ortego M, Tuñón J, Ortega L, Guijarro C, et al. Atorvastatin reduces lesion size and macrophage content in a rabbit model of atherosclerosis, and attenuates NF-κB activation and MCP-1 expression in cultured SMC (abstract). Atherosclerosis 1997;130:S7.
34. Russell ME, Wallace AF, Wyner LR, Newell JB, Karnovsky MJ. Upregulation and modulation of inducible nitric oxide synthase in rat cardiac allografts with chronic rejection and transplant arteriosclerosis. Circulation 1995;92:457-64.
35. Ravalli S, Albala A, Ming M, Szabolcs M, Barbone A, Michler RE, et al. Inducible nitric oxide synthase expression in smooth muscle cells and macrophages of human transplant coronary artery disease. Circulation 1998;97:2338-45.